Reply schreef op 10 maart 2020 13:01:
[...]
U denkt toch niet dat Kiadis vanochtend speciaal een Pb heeft uitgebracht omdat men nieuwe onderzoeks data heeft welke negatief zou zijn?!Men heeft juist nieuwe overtuigende data waarbij Kiadis het voor hen juiste podium kiest hier verder op in te gaan met andere deskundige wetenschappers:
Results: NK cell production was feasible for all subjects. 13 patients were treated (one treated twice), age 1-61y (median 22y), with primary refractory (n= 5) or relapsed (n=8) AML. Patients had a median of five prior therapies, including nine with prior stem cell transplantation. Two patients had CNS, one bone and nerve root disease and one CNS probable mycetoma. Therapy was tolerated with manageable toxicity in such an ill population of patients. Median neutrophil and platelet recovery were at day 33 and 44, respectively. Complete response and overall response rate were 50% and 78.5%, respectively, including unexpected CNS responses that were associated with localized inflammation. Median OS and DFS after treatment were 271 and 90 days, respectively.
Conclusions: Repeated infusions of high doses of cryopreserved expanded NK cells are feasible and well-tolerated after high-dose chemotherapy and demonstrate encouraging systemic and CNS responses in high-risk AML.
www.professionalabstracts.com/ebmt202...